Boehringer Ingelheim’s phosphodiesterase 4B (PDE4B) inhibitor nerandomilast has demonstrated efficacy in a second Phase III trial, this time in patients with progressive pulmonary fibrosis (PPF). The company announced on 10 February that it will file nerandomilast with the US Food and Drug Administration and other global regulators for both PPF and idiopathic pulmonary fibrosis (IPF).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?